Results 221 to 230 of about 1,795,367 (304)

Spinal Myeloid Sarcoma Revealing Acute Myeloid Leukemia in a Child: A Case Report. [PDF]

Cureus
Azizi M, Tkak H, Abderrahmani A, Haloui A, Bennani A, Seddik R, Ghanam A.   +6 more
europepmc   +1 more source

Effects of proton therapy on the tumor immune system and clinical implications: A review

Precision Radiation Oncology, EarlyView.
Proton therapy is a novel radiotherapy technique. We review four aspects of proton therapy: application in various tumors, effects on the tumor immune system, combination with other therapies, and future challenges. By presenting these aspects in this review, we aim to inspire clinical interventions.
Rundong Liu, Mei Tao, Min Fu, Yingjia Hu, Zhen Tao, Guangyuan Hu   +5 more
wiley   +1 more source

Pulmonary Leukemic Infiltration in Relapsed Acute Myeloid Leukemia: A Case Report. [PDF]

Clin Case Rep
Mortezazadeh M, Safaei SR, Nejad AM, Seyyed Mahmoudi ST, Aghajani SH, Nozheh A, Chaboki AM.   +6 more
europepmc   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia. [PDF]

Leukemia
Lee D, Abu-Shihab Y, Plas K, Nicolet D, Mrózek K, Routbort MJ, Patel KP, Walker CJ, Buss J, Stiff AR, Laganson A, DiNardo CD, Daver NG, Kadia TM, Ravandi F, Carroll AJ, Kolitz JE, Powell BL, Blum WG, Baer MR, Marcucci G, Uy GL, Stock W, Stone RM, Medeiros LJ, Byrd JC, Blachly JS, Bowman RL, Tyner JW, Loghavi S, Eisfeld AK, Miles LA.   +31 more
europepmc   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Epigenetic Regulation in Acute Myeloid Leukemia: Molecular Mechanisms and Clinical Implications. [PDF]

Cancers (Basel)
Xu J, Lacaud G.
europepmc   +1 more source

Piper nigrum Has an Antitumor Effect Through Regulation of the Phosphatidylinositol 3‐Kinase Signaling Pathway in a Murine Model of Acute Myeloid Leukemia

Phytotherapy Research, EarlyView.
Overview of the antileukemic effects of Piper nigrum extract in AML. P. nigrum reduced leukemic cell proliferation and glycolytic metabolism through modulation of the PI3K/AKT/mTOR pathway. In vivo, treatment reduced leukemic burden, improved hematological parameters, prolonged survival, and modulated antitumor immune responses.
Natalia Murillo, Paola Lasso, Claudia Urueña, Susana Fiorentino   +3 more
wiley   +1 more source

From transcriptomic profiling to precision oncology: a bibliometric analysis of RNA sequencing in acute myeloid leukemia. [PDF]

Front Med (Lausanne)
Ren Y, Ma J, Hu W, Zhang L, Wang X.
europepmc   +1 more source